ACRS
Aclaris Therapeutics, Inc.
There isn't enough reported data to score ACRS yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
ACRS Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Unavailable |
ACRS's revenue, profitability and cash flow are currently weak. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ACRS PE Valuation
ACRS has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
ACRS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Decline | |
| -- | |
| Limited | |
| Low |
Analysts expect ACRS's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
ACRS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.58 | +$1.00 |
| Q2 2026 | -$0.58 | +$0.99 |
| Q1 2026 | -$0.56 | +$1.03 |
| Q4 2025 | -$0.53 | +$1.18 |
| Q3 2025 | -$1.58 | -$1.06 |
| Q2 2025 | -$1.57 | -$0.75 |
| Q1 2025 | -$1.59 | -$0.50 |
| Q4 2024 | -$1.71 | -$0.44 |
ACRS is still losing money, but far less than before: $0.58 per share over the past year, against $3.90 at its worst in late 2019.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over ACRS on earnings quality, reporting a profit while its opponent remains loss making.
ACRS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.5M | -55% |
| Q2 2026 | $1.6M | -8.3% |
| Q1 2026 | $2M | +37% |
| Q4 2025 | $1.3M | -86% |
| Q3 2025 | $3.3M | -24% |
| Q2 2025 | $1.8M | -36% |
| Q1 2025 | $1.5M | -39% |
| Q4 2024 | $9.2M | -48% |
ACRS's revenue has slid since its 2022 peak: $1M last quarter, down 55% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1441% | -921 points |
| Q2 2026 | -1488% | -452 points |
| Q1 2026 | -1112% | +131 points |
| Q4 2025 | -1756% | -673 points |
| Q3 2025 | -520% | -279 points |
| Q2 2025 | -1036% | -571 points |
| Q1 2025 | -1243% | -453 points |
| Q4 2024 | -1082% | -1059 points |
ACRS's operating margin was −1441% last quarter, down 921 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over ACRS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over ACRS on profitability, with a higher operating margin.
ACRS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$24.1M | -$13.1M |
| Q2 2026 | -$19.9M | -$9.9M |
| Q1 2026 | -$18.2M | -$5.1M |
| Q4 2025 | -$13.2M | -$4.2M |
| Q3 2025 | -$11M | -150% |
| Q2 2025 | -$10M | +$2.3M |
| Q1 2025 | -$13.1M | +$7.9M |
| Q4 2024 | -$8.9M | -$1.7M |
ACRS has burned cash in almost every quarter: −$75M over the past year, against −$43M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over ACRS on cash generation, producing positive trailing cash flow while its opponent burns cash.
ACRS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.7% | +6.7M shares |
| 1 year | +22% | +26.8M shares |
| 3 years | +112% | +78.8M shares |
| 5 years | +177% | +95.5M shares |
| Available history | +262% | +108M shares |
ACRS has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ACRS Net Leverage
ACRS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
ACRS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.9 | Neutral |
| Stochastic | 22.7 | Neutral |
ACRS's weekly RSI is 44 (neutral) and its Stochastic is 23 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ACRS PE vs Healthcare Sector
ACRS has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
ACRS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.03 | 0.7% below |
| 20 week MA | $5.03 | 20% below |
| 50 week MA | $4.27 | 6.3% below |
| 100 week MA | $3.09 | 29% above |
| 200 week MA | $3.91 | 2.3% above |
ACRS has slipped below its 8-, 20- and 50-week averages, though it's still 2.3% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over ACRS on trend strength, trading above more of its moving averages.
ACRS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.92 | $7.61 | +296% |
| 2021 | $7.61 | $15.4 | +103% |
| 2022 | $15.4 | $15.1 | -2.3% |
| 2023 | $15.1 | $1.05 | -93% |
| 2024 | $1.05 | $2.73 | +160% |
| 2025 | $2.73 | $3.03 | +11% |
| 2026 YTD | $3.03 | $4.00 | +32% |
ACRS's yearly returns have swung widely, from +296% in 2020 to −93% in 2023. It's up 32% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over ACRS on returns for 2026, with the stronger performance.